Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kathleen Colson"'
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
L. Sun, Eileen Reilly, Syed Rizvi, Carol Oerth, Laura McBride, Constantine S. Mitsiades, Judy Chiao, Kathleen Colson, Ivy Fearen, Justin L. Ricker, Paul G. Richardson, Kenneth C. Anderson, Barbara Atkins, David Siegel
Publikováno v:
Leukemialymphoma. 49(3)
A Phase I trial (NCT00109109) of oral vorinostat 200, 250 or 300 mg twice daily for 5 days/week/4-week cycle or 200, 300, or 400 mg twice daily for 14 days/3-week cycle until progressive disease or intolerable toxicity was conducted. Patients with me
Autor:
Anuj Mahindra, Nikhil C. Munshi, Linda Rivera, Ayman Saad, Irene M. Ghobrial, Sarah Kaster, Kenneth C. Anderson, Noopur Raje, Aliyah R. Sohani, Paulette Jacobs, Edie Weller, Paul G. Richardson, Robert L. Schlossman, Jacob P. Laubach, Wendy Makrides, Parameswaran Hari, Jill N. Burke, Jennifer Adams, Kathleen Colson, Christine Connolly
Publikováno v:
Blood. 116:3051-3051
Abstract 3051 Background: Lenalidomide (Revlimid®, Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (MM) patients following ≥1 prior therapy. RAD001, an mTOR inhibitor has been studied as a sin
Autor:
Dixie-Lee Esseltine, Melissa Alsina, Irene M. Ghobrial, Kathleen Colson, Paul G. Richardson, John Feather, Nikhil C. Munshi, Laura E. Lunde, Robert L. Schlossman, Sagar Lonial, Kenneth C. Anderson, Robert Knight, Andrzej Jakubowiak, Sundar Jagannath, Teru Hideshima, David H. Vesole, Constantine S. Mitsiades, Mary McKenney, Amitabha Mazumder, Noopur Raje
Publikováno v:
Blood. 116:3049-3049
Abstract 3049 Background: Single-agent bortezomib (btz) and lenalidomide (len)-dexamethasone (dex) are associated with higher rates of response and improved survival vs dex alone in relapsed MM, and both are approved for treatment of MM pts with ≥1
Autor:
Constantine S. Mitsiades, Kenneth C. Anderson, Kara Kosakowski, Sundar Jagannath, Amitabha Mazumder, Melissa Alsina, Sagar Lonial, Laura E. Lunde, Kathleen Colson, Nikhil C. Munshi, Irene M. Ghobrial, Noopur Raje, Sarah Kennedy, Teru Hideshima, Dixie-Lee Esseltine, Andrzej Jakubowiak, Robert Knight, David H. Vesole, Paul G. Richardson, Mary McKenney
Publikováno v:
Blood. 112:1742-1742
Background: Bortezomib (VELCADE®, Bz) is approved for the treatment of multiple myeloma (MM). Lenalidomide (Revlimid®, Len) plus dexamethasone (Dex) is approved for the treatment of relapsed MM pts following ≥ 1 prior therapy. In a phase 1 study,
Autor:
Ivy Fearen, Kenneth C. Anderson, Paul G. Richardson, David S. Siegel, Syed Rizvi, L. Sun, Barbara Atkins, Laura McBride, Carol Oerth, Eileen Reilly, Constantine S. Mitsiades, Judy Chiao, Kathleen Colson, Justin L. Ricker
Publikováno v:
Blood. 110:1179-1179
Background: The histone deacetylase inhibitor vorinostat was approved by the United States FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent dise
Autor:
John J. Densmore, Paul G. Richardson, KC Anderson, L. Gardner, Tara Kendall, Jeffrey P. Allerton, Irene M. Ghobrial, Kathleen Colson, Teru Hideshima, Jeffrey A. Zonder, Aparna Krishnan, Robert Birch, Andrzej Jakubowiak, Thierry Facon, Peter Sportelli, B. Martineau, C. Leister, Jeffrey L. Wolf, Sagar Lonial, I. C. Henderson
Publikováno v:
Blood. 110:1170-1170
INTRODUCTION: Perifosine (peri) is an oral, signal transduction modulator with multiple pathway effects including inhibition of Akt and activation of JNK. In vitro, peri + bortezomib (Velcade®, Vel) shows additive cytotoxicity against MM cells with
Autor:
Anna Stepanek, Nikhil C. Munshi, Paul G. Richardson, Laura E. Lunde, Reggie Michelle, Nicholas Mitsiades, Robert L. Schlossman, Deborah Doss, Svetlana Gorelik, Constantine S. Mitsiades, Stephen Hayes, Andrea Freeman, Victoria M. Richon, Kathleen Colson, Diane Warren, Mary McKenney, Keith Doucet, Judi Chiao, Kenneth C. Anderson, Karyn Dinand, Karen Hande
Publikováno v:
Blood. 104:1503-1503
Introduction: Histone deacetylases (HDACs) affect cell growth at the transcriptional level by regulating the acetylation status of nucleosomal histones, and HDAC inhibition induces differentiation and/or apoptosis in transformed cells. We have recent